6-K filed Sep 3, 2026 at 06:04 ET
HUTCHMED announced an exclusive worldwide licensing agreement with GSK for HMPL-A830, a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC) for colorectal, pancreatic, and lung cancers. The deal includes a $110 million upfront payment and up to $1.295 billion in total milestones plus tiered royalties, with HUTCHMED retaining rights in Greater China. This is a major non-dilutive validation of HUTCHMED's ATTC platform and provides significant near-term cash, though the asset is still pre-clinical with Phase I starting H2 2026.